Table 2 Cohort Descriptions
From: Identifying pathways to the prevention of dementia: the Netherlands consortium of dementia cohorts
Name | Partner | Short Description |
|---|---|---|
Amsterdam Dementia Cohort (ADC)[3] | VUmc-AC | Aim: To study the causes and outcomes of neurodegenerative disorders Setting: Memory clinic Start: 2000 Number of participants:1041 Data collection: Clinical and cognitive data, MRI, EEG, blood, DNA, CSF AD biomarkers Follow-up: Annual follow-up (clinical) |
Doetinchem Cohort Study (DCS)[4] | RIVM | Aim: To provide insight in changes over the life course in lifestyle, metabolic risk factors and health, and the relation between risk factors and disease Setting: Population-based Start: 1987 Number of participants: 6000 Data collection: Clinical and cognitive data, lifestyle data, cardiometabolomic data, metabolomic and genomic data Follow-up: Every 5 years |
European Medical Information Framework for Alzheimer’s Disease (EMIF-AD)[5] | VUmc-AC | Aim: To allow for large-scale research on biomarkers and risk factors for neurodegenerative disorders Setting: Population-based Start: 2018 Number of participants: 313 Data collection: Clinical and cognitive data, MRI, blood, DNA, PET Follow-up: Annual |
VUmc-APH | Aim: A longitudinal study on daily functioning and well-being of older persons, interdisciplinary Setting: Population-based Start: 1992 Number of participants: 5132 Data collection: Cognitive data, psychosocial data, blood, DNA Follow-up: Every 3–4 years | |
Leiden Longevity Study (LLS)[8] | LUMC | Aim: To study the determinants and biomarkers of healthy ageing and longevity Setting: Research cohort, a two-generational study Start:2003 Number of participants: 944 (90+), offspring (2415) Data collection: Clinical and cognitive data, MRI, data on environmental exposures, metabolomic and genomic data Follow-up:20 years |
The Maastricht Study | MUMC-IG | Aim: To study the complications of type II diabetes Setting: Population-based Start: 2010 Number of participants: 9200 Data collection: Clinical and cognitive data, psychosocial data, plasma markers, MRI, DNA, lifestyle data Follow-up: Ongoing |
Memolife substudy of Lifelines | UMCG | Aim: Investigating complex interactions between environmental, phenotypic and genomic factors in the development of chronic diseases and healthy aging. Setting: Population-based three-generation cohort Start:2006 Number of participants:281 Data collection: Clinical data, MRI, plasma, blood, urine, DNA Follow-up: Every 5 years |
EMC | Aim: To study the determinants, pre-clinical development and prognosis of chronic disease in the elderly Setting: Population-based Start:1990 Number of participants: 14.926 Data collection: Clinical and cognitive data, psychosocial data, functional outcome data, MRI, PET, data on environmental exposures, metabolomic and genomic data Follow-up: Every 3–4 years | |
Second Manifestations of ARTerial disease-Magnetic Resonance (SMART-MR) study | UMCU | Aim: To investigate risk factors and consequences of brain changes on MRI in patients with symptomatic atherosclerotic disease. Setting: Hospital; persons newly referred to the UMCU for treatment of manifest atherosclerotic disease Start: 2001 Number of participants: 1309 Data collection: Clinical and cognitive data, psychosocial data, plasma markers, MRI, DNA Follow-up: Every 5 years |